Plasma Proteomics of COVID-19-Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics

JACC Basic Transl Sci. 2022 May;7(5):425-441. doi: 10.1016/j.jacbts.2022.01.013. Epub 2022 May 4.

Abstract

To gain insights into the mechanisms driving cardiovascular complications in COVID-19, we performed a case-control plasma proteomics study in COVID-19 patients. Our results identify the senescence-associated secretory phenotype, a marker of biological aging, as the dominant process associated with disease severity and cardiac involvement. FSTL3, an indicator of senescence-promoting Activin/TGFβ signaling, and ADAMTS13, the von Willebrand Factor-cleaving protease whose loss-of-function causes microvascular thrombosis, were among the proteins most strongly associated with myocardial stress and injury. Findings were validated in a larger COVID-19 patient cohort and the hamster COVID-19 model, providing new insights into the pathophysiology of COVID-19 cardiovascular complications with therapeutic implications.

Keywords: ADAMTS13, A Disintegrin And Metalloproteinase with a Thrombospondin type 1 motif, member 13; COVID-19; FSTL3, follistatin-like 3; NT-proBNP, N-terminal pro–B-type natriuretic peptide; SASP, senescence associated secretory phenotype; TGFβ, transforming growth factor beta; hsTnT, high sensitivity troponin T; myocardial injury; proteomics; senescence.